Ensign Peak Advisors’s Pacira BioSciences PCRX Stock Holding History

Ensign Peak Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$117K	Sell	4,620 -250	-5%	-$5.91K	﹤0.01%	1574
2026 Q1	$110K	Hold	4,870	–	–	﹤0.01%	1541
2025 Q4	$126K	Sell	4,870 -13,450	-73%	-$320K	﹤0.01%	1509
2025 Q3	$472K	Sell	18,320 -2,700	-13%	-$66.3K	﹤0.01%	1408
2025 Q2	$502K	Hold	21,020	–	–	﹤0.01%	1553
2025 Q1	$522K	Hold	21,020	–	–	﹤0.01%	1537
2024 Q4	$396K	Hold	21,020	–	–	﹤0.01%	1651
2024 Q3	$316K	Hold	21,020	–	–	﹤0.01%	1669
2024 Q2	$601K	Hold	21,020	–	–	﹤0.01%	1552
2024 Q1	$614K	Sell	21,020 -1,060	-5%	-$32.6K	﹤0.01%	1575
2023 Q4	$745K	Hold	22,080	–	–	﹤0.01%	1537
2023 Q3	$677K	Hold	22,080	–	–	﹤0.01%	1460
2023 Q2	$885K	Hold	22,080	–	–	﹤0.01%	1361
2023 Q1	$901K	Hold	22,080	–	–	﹤0.01%	1328
2022 Q4	$853K	Buy	22,080 +5,400	+32%	+$263K	﹤0.01%	1290
2022 Q3	$887K	Sell	16,680 -1,750	-9%	-$97.3K	﹤0.01%	1136
2022 Q2	$1.07M	Hold	18,430	–	–	﹤0.01%	1081
2022 Q1	$1.41M	Hold	18,430	–	–	﹤0.01%	1033
2021 Q4	$1.11M	Sell	18,430 -9,170	-33%	-$506K	﹤0.01%	1222
2021 Q3	$1.55M	Hold	27,600	–	–	﹤0.01%	1250
2021 Q2	$1.68M	Hold	27,600	–	–	﹤0.01%	1221
2021 Q1	$1.93M	Buy	27,600 +2,300	+9%	+$164K	﹤0.01%	1130
2020 Q4	$1.51M	Buy	25,300 +5,500	+28%	+$322K	﹤0.01%	1212
2020 Q3	$1.19M	Hold	19,800	–	–	﹤0.01%	1235
2020 Q2	$1.04M	Hold	19,800	–	–	﹤0.01%	1266
2020 Q1	$664K	Buy	19,800 +10,500	+113%	+$436K	﹤0.01%	1309
2019 Q4	$421K	Buy	+9,300	New	+$395K	﹤0.01%	1538

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ensign Peak Advisors's PCRX Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Pacira BioSciences (PCRX) stake by 5.1% in Q2 2026, selling an estimated $5.91K and leaving 4,620 shares worth $117K. The position accounts for ﹤0.01% of the portfolio, ranked #1574.

Ensign Peak Advisors first reported a position in PCRX in Q4 2019 and has held it in 27 quarters since. The position peaked at $1.93M in Q1 2021. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

Ensign Peak Advisors held 4,620 shares of Pacira BioSciences worth $117K as of Q2 2026.
Ensign Peak Advisors sold 250 Pacira BioSciences shares in Q2 2026, an estimated $5.91K.
Pacira BioSciences made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #1574 holding.
Ensign Peak Advisors first reported a position in Pacira BioSciences in Q4 2019 and has held it in 27 quarters since.
Ensign Peak Advisors's Pacira BioSciences position peaked at $1.93M in Q1 2021.
253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.